• News

    Department of Defense Armed Forces Institute of Regenerative Medicine – II (AFIRM II)

    Date: April 15, 2012

    The Armed Forces Institute of Regenerative Medicine (AFIRM) is soliciting applications for the AFIRM II program, which is anticipated to be funded in Fiscal Year 2013 (FY13).  Goals of the program include positioning promising technologies and therapeutic/restorative practices for entrance into human clinical trials. The intent of the AFIRM II program is to fund basic through translational regenerative medicine research and development. Activities acceptable under this award may include basic scientific research, development of animal models, preclinical studies required for initiation of FDA-regulated human clinical trials, and Phase I – II human clinical trials.  Alignment with relevant ongoing Department of Defense (DoD) research effort(s) and collaboration with DoD researchers and clinicians focused on research relevant to the health care needs of the Armed Forces is encouraged.

    It is the intent to make one award that appropriately addresses all five focus areas of the program (Extremity Regeneration, Craniomaxillofacial Regeneration, Skin Regeneration, Composite Tissue Allotransplantation and Immunomodulation and Genitourinary/Lower Abdomen Reconstruction).  However, multiple awards may be made to ensure that all five focus areas are addressed under the AFIRM II project.

    The current funding level for all awards is anticipated to be $15 million per year over five years for a total of $75 million, subject to the availability of funds.  Proposals submitted with less than five focus areas should contain a budget that is in direct proportion to the total funding made available for this project.


    Pre-Application (Letter of Intent) Submission Deadline:

    5:00 p.m. Eastern time (ET), July 2, 2012

    Application Submission Deadline: 11:59 p.m. ET, July 11, 2012 Scientific Peer Review: August 2012
Programmatic Review: November 2012


    For more information see:


This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Policies and Procedures for more details